论文部分内容阅读
目的探讨维格列汀联合门冬胰岛素30注射液治疗老年2型糖尿病的临床疗效和安全性。方法选取2013年7月至2014年7月在我院接受治疗的老年2型糖尿病患者68例为研究对象,按照随机数字表法随机分为联合治疗组和对照组,每组34例;联合治疗组给予维格列汀联合门冬胰岛素30注射液治疗,对照组给予门冬胰岛素30注射液治疗,观察两组治疗前后空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1C)水平,并比较两组患者胰岛素用量、低血糖反应发生情况。结果与治疗前相比,治疗3个月后联合治疗组和对照组FPG、2 h PG及Hb A1C水平均明显降低,差异均有统计学意义(P<0.05),且治疗后联合治疗组FPG、2 h PG及Hb A1C均明显低于对照组,差异均有统计学意义(P<0.05)。联合治疗组胰岛素用量[(0.56±0.22)U·kg-1·d-1]明显低于对照组[(0.78±0.34)U·kg-1·d-1],差异有统计学意主(P<0.05)。联合治疗组体质指数与治疗前相比,差异无统计学意义(P>0.05);而对照组治疗后体质指数较治疗前明显增加,差异有统计学意义(P<0.05);且两组治疗后体质指数的差异有统计学意义(P<0.05)。联合治疗组低血糖发生率(5.9%)低于对照组(32.3%),差异有统计学意义(P<0.05)。联合治疗组总有效率(94.1%)高于对照组(82.4%),差异有统计学意义(P<0.05)。结论维格列汀联合门冬胰岛素30注射液可使老年2型糖尿病患者血糖得到控制,低血糖发生率低,且安全性高,值得临床推广和应用。
Objective To investigate the clinical efficacy and safety of vegliptin in combination with insulin aspart 30 injection in the treatment of type 2 diabetes in the elderly. Methods Sixty-eight elderly patients with type 2 diabetes mellitus treated in our hospital from July 2013 to July 2014 were selected as study subjects and randomly divided into the combined treatment group and control group according to the random number table method, with 34 cases in each group. The patients were treated with veglnitidine combined with insulin aspart 30 injection, and the control group with insulin aspart 30 injection. The levels of fasting blood glucose (FPG), 2 h postprandial glucose (2 h PG), glycosylated hemoglobin (Hb A1C) levels, and compared the two groups of patients with insulin dosage, hypoglycemia response. Results Compared with those before treatment, the levels of FPG, 2 h PG and Hb A1C in the combination therapy group and the control group were significantly decreased after 3 months of treatment, with statistical significance (P <0.05). After treatment, FPG , 2 h PG and Hb A1C were significantly lower than the control group, the difference was statistically significant (P <0.05). Compared with the control group [(0.78 ± 0.34) U · kg-1 · d-1], the insulin dosage in the combined treatment group was significantly lower than that in the control group [(0.56 ± 0.22) U · kg-1 · d-1] P <0.05). Compared with before treatment, the body mass index in the combination therapy group had no significant difference (P> 0.05), while the body mass index in the control group was significantly increased after treatment compared with before treatment, the difference was statistically significant (P <0.05) Body mass index after the difference was statistically significant (P <0.05). The incidence of hypoglycemia in the combined treatment group (5.9%) was lower than that in the control group (32.3%), with significant difference (P <0.05). The total effective rate (94.1%) in the combined treatment group was higher than that in the control group (82.4%), with significant difference (P <0.05). Conclusion Vildagliptin combined with insulin aspart 30 injection can control the blood glucose of elderly type 2 diabetic patients with low incidence of hypoglycemia and high safety, which is worthy of clinical promotion and application.